Resmed's $490M Sale Looks Strategically Sound

Dow Jones

Jul 09

0054 GMT - ResMed's $490 million sale of its MatrixCare business looks strategically sound to its bull at Macquarie. One of the investment bank's analysts writes in a note that the divestment will allow the dual-listed breath-tech maker to sharpen its focus and to reallocate capital toward faster-growing core growth areas. Offloading a structurally challenged business and improving the company's growth profile makes sense to the analyst, who keeps an outperform rating on the stock. Stock catalysts include potential M&A activity and new product launches, the analyst adds. Macquarie lifts its target price on ResMed's ASX-listed stock by 0.2% to 46.60 Australian dollars. Shares are down 3.8% at A$29.995. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 08, 2026 20:54 ET (00:54 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2650912678"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650912678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650912678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 08:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650912678","market":"hk","top_or_hot":-1,"title":"Resmed's $490M Sale Looks Strategically Sound","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0054 GMT - ResMed's $490 million sale of its MatrixCare business looks strategically sound to its bull at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>. One of the investment bank's analysts writes in a note that the divestment will allow the dual-listed breath-tech maker to sharpen its focus and to reallocate capital toward faster-growing core growth areas. Offloading a structurally challenged business and improving the company's growth profile makes sense to the analyst, who keeps an outperform rating on the stock. Stock catalysts include potential M&amp;A activity and new product launches, the analyst adds. Macquarie lifts its target price on ResMed's ASX-listed stock by 0.2% to 46.60 Australian dollars. Shares are down 3.8% at A$29.995. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 20:54 ET (00:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Resmed's $490M Sale Looks Strategically Sound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResmed's $490M Sale Looks Strategically Sound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-09 08:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0054 GMT - ResMed's $490 million sale of its MatrixCare business looks strategically sound to its bull at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>. One of the investment bank's analysts writes in a note that the divestment will allow the dual-listed breath-tech maker to sharpen its focus and to reallocate capital toward faster-growing core growth areas. Offloading a structurally challenged business and improving the company's growth profile makes sense to the analyst, who keeps an outperform rating on the stock. Stock catalysts include potential M&amp;A activity and new product launches, the analyst adds. Macquarie lifts its target price on ResMed's ASX-listed stock by 0.2% to 46.60 Australian dollars. Shares are down 3.8% at A$29.995. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 20:54 ET (00:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4567","symbol_name":"ESG概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2650912678","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650912678","pubTimestamp":1783558440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0054 GMT - ResMed's $490 million sale of its MatrixCare business looks strategically sound to its bull at Macquarie. One of the investment bank's analysts writes in a note that the divestment will allow the dual-listed breath-tech maker to sharpen its focus and to reallocate capital toward faster-growing core growth areas. Offloading a structurally challenged business and improving the company's growth profile makes sense to the analyst, who keeps an outperform rating on the stock. Stock catalysts include potential M&A activity and new product launches, the analyst adds. Macquarie lifts its target price on ResMed's ASX-listed stock by 0.2% to 46.60 Australian dollars. Shares are down 3.8% at A$29.995.  Dow Jones NewswiresJuly 08, 2026 20:54 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4567":"ESG概念","BK4548":"巴美列捷福持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4082":"医疗保健设备","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK4504":"桥水持仓","BK7501":"新冠治疗股","BK7007":"医疗保健设备","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","RMD.AU":"Resmed DRC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","RMD":"瑞思迈","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"瑞思迈4.9亿美元的出售看起来战略合理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGHT":0.6,"RMD.AU":0.9,"RMD":0.9},"content_text":"0054 GMT - ResMed's $490 million sale of its MatrixCare business looks strategically sound to its bull at Macquarie. One of the investment bank's analysts writes in a note that the divestment will allow the dual-listed breath-tech maker to sharpen its focus and to reallocate capital toward faster-growing core growth areas. Offloading a structurally challenged business and improving the company's growth profile makes sense to the analyst, who keeps an outperform rating on the stock. Stock catalysts include potential M&A activity and new product launches, the analyst adds. Macquarie lifts its target price on ResMed's ASX-listed stock by 0.2% to 46.60 Australian dollars. Shares are down 3.8% at A$29.995. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2026 20:54 ET (00:54 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}